Detalles de la búsqueda
1.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37086745
2.
Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat
; 2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38722442
3.
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Breast Cancer Res Treat
; 197(2): 355-368, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36409394
4.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med
; 379(8): 753-763, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30110579
5.
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Breast Cancer Res
; 22(1): 27, 2020 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164785
6.
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Oncologist
; 25(3): e439-e450, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162822
7.
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Breast Cancer Res Treat
; 184(1): 23-35, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32783178
8.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32683565
9.
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
BMC Cancer
; 20(1): 1091, 2020 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33176725
10.
First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
Arch Gynecol Obstet
; 302(6): 1461-1467, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32902674
11.
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Oncologist
; 24(12): 1514-1525, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31217344
12.
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Breast Cancer Res Treat
; 173(2): 319-328, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30324275
13.
Translational highlights in breast cancer research and treatment: recent developments with clinical impact.
Curr Opin Obstet Gynecol
; 31(1): 67-75, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520757
14.
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Anticancer Drugs
; 29(3): 271-280, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29360661
15.
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network.
Arch Gynecol Obstet
; 295(5): 1239-1245, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28331996
16.
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Breast Cancer Res
; 18(1): 67, 2016 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27349747
17.
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.
Breast Cancer Res Treat
; 158(1): 59-65, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27283834
18.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Lancet Oncol
; 16(1): 25-35, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25524798
19.
Short-term and long-term outcome of radiological-guided insertion of central venous access port devices implanted at the forearm: a retrospective monocenter analysis in 1704 patients.
Eur Radiol
; 25(3): 606-16, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25239184
20.
ABC7 Consensus: Assessment by a German Group of Experts.
Breast Care (Basel)
; 19(2): 116-128, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38638343